Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

337
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
337
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

191
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
191
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.0K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.0K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

2.0K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

331
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
331
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

204
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
204

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024
Same author

Overcoming barriers to deliver high quality kidney care.

Nature reviews. Nephrology·2024
Same author

Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research.

Canadian journal of kidney health and disease·2024
Same author

Kidney biopsies among persons living in hotspots of CKDu: a position statement from the International Society of Nephrology's Consortium of Collaborators on CKDu.

Kidney international·2023
Same author

Patient and Clinician Experiences With the Combination of Virtual and In-Person Chronic Kidney Disease Care Since the COVID-19 Pandemic.

Canadian journal of kidney health and disease·2023
Same author

Predicting Outcomes in Nephrology: Lots of Tools, Limited Uptake: How Do We Move Forward?

Journal of the American Society of Nephrology : JASN·2023

Video Experimental Relacionado

Updated: Nov 18, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K

Efectos de la presión arterial de la canagliflozina y resultados clínicos en la diabetes tipo 2 y la enfermedad renal

Nan Ye1,2, Meg J Jardine1,3, Megumi Oshima1,4

  • 1The George Institute for Global Health (N.Y., M.J.J., M.O., C.H., A.E.S., C.A., B.N., D.C.W., G.L.D.T., V.P., B.L.N.), University of New South Wales, Sydney, Australia.

Circulation
|February 8, 2021
PubMed
Resumen

La canagliflozina reduce eficazmente la presión arterial sistólica (PA) en pacientes con diabetes tipo 2 y enfermedad renal crónica, independientemente de la PA basal o de la medicación. Este inhibidor de SGLT2 también reduce la necesidad de medicamentos adicionales para la presión arterial y protege contra eventos renales y cardiovasculares.

Palabras clave:
Inhibidores de la SGLT2Presión arterialEl uso de canagliflozinaEnfermedad renal crónicahipertensión

Más Videos Relacionados

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

442

Videos de Experimentos Relacionados

Last Updated: Nov 18, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

442

Área de la Ciencia:

  • Nefrología
  • Cardiología
  • Endocrinología

Sus antecedentes:

  • La diabetes tipo 2 y la enfermedad renal crónica (ERC) comúnmente coexisten con la hipertensión.
  • El impacto de la canagliflozina en la presión arterial (PA) y su consistencia en todos los subgrupos de pacientes de esta población no está claro.

Objetivo del estudio:

  • Investigar el efecto de la canagliflozina en la presión arterial sistólica en pacientes con diabetes tipo 2 y ERC.
  • Determinar si los efectos de canagliflozina en la presión arterial y los resultados clínicos varían en función de la presión arterial basal o del tratamiento antihipertensivo.

Principales métodos:

  • Un análisis post hoc del ensayo CREDENCE, en el que los pacientes con diabetes tipo 2 y ERC fueron asignados al azar a canagliflozina o a placebo.
  • Se realizaron análisis de subgrupos basados en la presión arterial sistólica basal, el número de clases de fármacos para bajar la presión arterial y los antecedentes de hipertensión resistente.

Principales resultados:

  • Canagliflozin redujo la presión arterial sistólica en 3,50 mm Hg en 3 semanas, un efecto que se mantuvo durante todo el ensayo.
  • La reducción de la presión arterial y los beneficios de los resultados clínicos fueron consistentes en todos los subgrupos evaluados.
  • La canagliflozina disminuyó la probabilidad de iniciar la administración de otros fármacos reductores de la presión arterial (RH, 0,68).

Conclusiones:

  • La canagliflozina reduce efectivamente la presión arterial sistólica en pacientes con diabetes tipo 2 y ERC en diversos perfiles de presión arterial y regímenes de tratamiento.
  • Estos hallazgos apoyan el papel de la canagliflozina en la protección de los órganos terminales y como terapia adjunta para reducir la presión arterial en la ERC.
  • Canagliflozina demostró una reducción significativa de los eventos renales y cardiovasculares (RH, 0,70).